AIM·00901B303·US·equity·Healthcare - Biotechnology
AIM (AIM ImmunoTech Inc.) is held by 8 institutional investors as of Q4 2025. Largest holders: VANGUARD GROUP INC ($19,777), GEODE CAPITAL MANAGEMENT, LLC ($19,634), MORGAN STANLEY ($976). Net institutional sentiment: Mixed.
See how AIM's score breaks down across 4 SEC sources
Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer